제 목 : FROM ORGANIC CHEMISTRY TO MOLECULAR IMAGING: FUTURECHEM
연 사 : 지대윤 교수님(서강대학교 화학과)
일 시 : 2018년 11월 8일(목) 오후 4시 15분
장 소 : 화학관 1층 첨단강의실(330118호)
I. NEW FLUORINATION METHOD IN A NONPOLAR PROTIC ALCOHOL SOLVENTS
The typical method for introducing fluorine, which is the best PET radioisotope, at a specific aliphatic molecular site is the nucleophilic displacement of the corresponding sulfonate or halide by fluoride ion. Ten years ago, we have developed a remarkable effect of using tertiary alcohols as a reaction medium for nucleophilic fluorination with alkali metal fluorides. The great efficacy of this method is a particular advantage in labeling radiopharmaceuticals with [18F]fluorine in high yield and purity, and in shorter times compared to conventional syntheses. In this new mechanism, the bulky, polarizable cation separates F- from the protic solvent, which in turn acts as a base to reduce the unfavorable influence of the cation on the nucleophilicity of F-.
II. NEW PET RADIOPHARMACEUTICALS IN MARKET
After FDG has been used since 1980s commercially, new F-18 labeled commercial PET radiopharmaceuticals have not been lunched until 2008. Using this new fluorination method, two new radiopharmaceuticals [18F]FLT (cell proliferation imaging) and [18F]FP-CIT3 (Parkinson disease) were registered at Korea FDA in 2008. For your information, [18F]FLT and [18F]FP-CIT are commercially used for patients at Korea after getting the official permission from Korean FDA in 2008 spring. In 2002, 11C-labeled [11C]PIB (Pittsburgh compound B) was developed for imaging Aβ plaque in the brain of living subjects by modifying Thioflavin T, which has been used as a fluorescent dye for staining Aβ plaque in postmortem brains. [11C]PIB exhibited good Aβ plaque binding in a living brain with an appropriate brain accumulation and washout ratio. Three F-18 labeled PET tracers have been approved by the U.S. Food and Drug Administration (FDA) in 2012 (AmyvidTM, Eli Lilly), 2013 (VizamylTM, GE Healthcare), and 2014 (NeuraceqTM, Piramal) as Aβ imaging agents and a secondary tool for the diagnosis of AD. We have also developed fourth F-18 labeled Aβ imaging PET tracer in NDA by Korean FDA in 2018 (Alzavue®, FutureChem). Prostate cancer imaging including some therapeutics will be discussed.
III. DEVELOPEMNT OF NEW ORGANIC SYNTHESIS METHODOLOGIES
Some new organic synthesis methodologies will be discussed.